The authors evaluated the efficacy of neoadjuvant @entity3003 chemotherapy before external-beam irradiation in @entity1 who had histologically proven @entity463 multiforme. Twenty-five @entity1 were treated with @entity3003 , 600 mg/m2, intravenously once every 4 weeks for a total of 4 planned cycles. External-beam irradiation (60 Gy involved field) was planned after @entity3003 . Of 15 @entity1 who had @entity41 assessable for response, seven had stable disease, six had partial responses, one had a complete response, and one had progressive disease. Two of the @entity1 who had partial responses progressed before radiotherapy. Of 10 who had gross total resections, two progressed after 3 to 4 cycles. The median time to @entity5 progression was 8.4 months. Median survival was 19.2 months. Myelotoxicity and other side effects of treatment were modest. @entity3003 chemotherapy after biopsy or resection of @entity463 multiforme before irradiation is feasible. These results warrant further clinical investigation of the role that @entity3003 chemotherapy may have in the treatment of @entity1 who have newly diagnosed @entity463 multiforme.

XXXX chemotherapy before irradiation in newly diagnosed @entity463 multiforme.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin', 'carboplatin'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma']
@entity3003 :: (MESH:D016190,Chemical) :: ['Carboplatin']
